Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Determinants of the interindividual variability in response to antiplatelet drugsResistance to antiplatelet drugs: current status and future researchThe variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Aspirin and clopidogrel resistance: an emerging clinical entityCurrent strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesResponse to aspirin and clopidogrel monitored with different platelet function methodsEvidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and managementOral antiplatelet therapy and percutaneous coronary interventionClopidogrel resistance: myth or reality?Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problemsClopidogrel in the treatment of ischaemic heart diseasePlatelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Clopidogrel: an updated and comprehensive reviewCYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers.The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stentingPotential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyA case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Clopidogrel "resistance": where are we now?Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.Clinical importance of aspirin and clopidogrel resistanceIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.A population-based study of the drug interaction between proton pump inhibitors and clopidogrelTranscriptome analysis of artificial hybrid pufferfish Jiyan-1 and its parental species: implications for pufferfish heterosis.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Cardiovascular pharmacogenomicsEffect of gender difference on platelet reactivity.Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.Antiplatelet resistance and thromboembolic complications in neurointerventional procedures.Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress.In Vitro Assessment of Cytochrome P450 2C19 Potential of NaoxintongPlatelet activation in myocardial ischemic syndromes.Antiplatelet drugs: mechanisms and risks of bleeding following cardiac operationsPlatelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct ExpansionAssociation of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.
P2860
Q26801867-644CAC4B-D63C-4C7F-8873-1E30C2F69402Q27022443-946CA5B5-159C-4200-B7AC-463BA7472D71Q28187591-AB4E9078-AC0C-4419-BE21-62B623078355Q28192298-BA7E6D82-BD42-49C9-8B40-170B176EE7A8Q28192919-F92164D8-1470-4E87-8825-DBD3076CCDD9Q28194021-A351B894-3D60-4B2F-A53E-53F2E86D27EAQ28199725-3109CA07-A37B-4094-9447-266927697C1DQ28200256-F2C1ADC9-974C-4E9F-B8BF-EE8CB45724B6Q28200552-523FEECC-B0AD-4D91-81BC-E75AD7EC6F9AQ28200610-403A7CA3-D006-44A3-BBFE-509231738BD7Q28217724-47B75D07-A6DC-453D-AAAC-F971B7B97298Q28218055-8780F1EB-F286-47C8-A709-68C89EA0DCE5Q28218351-419BB7AA-49E6-4B64-9172-EB9066C66FFAQ28218576-7D1D023F-D921-48A3-B0A6-23D8FCFF2CC0Q28219354-F4A6BDF7-2A35-42C0-8814-C27020DEA1BBQ28219411-E8490B11-CFDE-4C04-970D-CC02CBF8FF5FQ33368192-BBA765D7-8EA1-4546-9755-A97E421F98CCQ33667262-3916A9A8-6F8B-4F3A-B089-B3DB00EDFD1BQ33776115-25004534-CADA-4E48-9FC3-74D0E02B46E2Q33818356-303E885C-8B88-479E-8FA3-A6560468D0C2Q33982372-A33E6758-ED7D-4F56-8ECB-E223DA4AD3AEQ34019082-B87BC522-0ABC-4CAC-AD26-8F28AB898E06Q34150640-A482FC40-0634-4E1A-8767-CF1A8CC23F59Q34212563-1A579E99-6D09-4C54-8FC2-B1C62118CACCQ34339780-993D15B0-09D8-498F-8C31-89A656E1EE8CQ34390050-ED39E4BE-C4B2-49FB-B4F1-374A21BBC69DQ34568130-6BE97716-0952-443D-9916-5AB707BF8681Q34603772-A6F116D1-1704-42F3-A3AD-62047B1D5FBAQ34631815-AFC19AEB-AAA8-4481-8F46-C0CE83AAE421Q34771381-12F5F5F6-35E7-4A62-95DA-A31D61D0391EQ35447163-F23137CC-7A59-42AD-8BFB-858E10790575Q35473568-9C07B087-A0EA-4275-ADBC-AF83D956141DQ35584682-A628AD5A-D37F-4A38-9657-3D2500FF13A5Q35750126-ACA1A2E2-68FC-4735-BE69-3AA978531655Q35792726-553D7B6B-71F9-46D5-BC94-DB60141C4576Q35796575-A26EB51E-6A95-43C6-AC11-9F74D1579C09Q35821899-E3635927-52E0-4173-9ACB-8BF117979373Q35902517-1589640C-DF04-499A-B161-B879B55C3671Q35940530-6ADED85B-8666-415A-99E2-F4126BD47AC7Q35951677-5D800D01-F84A-406A-93F6-1E08669E49E9
P2860
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@ast
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@en
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@nl
type
label
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@ast
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@en
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@nl
prefLabel
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@ast
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@en
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@nl
P2093
P1433
P1476
Contribution of hepatic cytoch ...... enon of clopidogrel resistance
@en
P2093
Alan R Tait
Amy S Hopp
Charlene J Neer
David G M Carville
Eric R Bates
Kirk E Guyer
Paul A Gurbel
Paul B Watkins
P304
P356
10.1161/01.CIR.0000112378.09325.F9
P407
P577
2004-01-20T00:00:00Z